BioCorRx to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 06, 2022 08:30 ET
|
BioCorRx Inc
ANAHEIM, CA, Sept. 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and...
BioCorRx Provides Business Update for the Second Quarter of 2022
August 16, 2022 08:30 ET
|
BioCorRx Inc
ANAHEIM, CA, Aug. 16, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and...
BioCorRx to Participate in the Benzinga All Access Event on July 15th
July 13, 2022 08:30 ET
|
BioCorRx Inc
ANAHEIM, CA, July 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and...
BioCorRx Announces First Subject Dosed in Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
June 30, 2022 09:00 ET
|
BioCorRx Inc
ANAHEIM, CA, June 30, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and...
BioCorRx Featured on LiveNOW from FOX
June 17, 2022 09:00 ET
|
BioCorRx Inc
ANAHEIM, CA, June 17, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and...
BioCorRx to Present at the LD Micro Invitational XII on June 7th
May 31, 2022 09:00 ET
|
BioCorRx Inc
ANAHEIM, CA, May 31, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and...
BioCorRx and 2B3D to Pilot First-of-its-Kind PTSD and Addiction Treatment Solutions for Veterans in Metaverse Setting
May 19, 2022 08:00 ET
|
BioCorRx Inc
Collaboration to create a synergistic treatment offering, combining BioCorRx’s MAT treatment program and 2B3D virtual reality technology Plans toward expanding the offering to other at-risk groups...
BioCorRx Business Update for the First Quarter of 2022
May 17, 2022 08:30 ET
|
BioCorRx Inc
ANAHEIM, CA, May 17, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and...
BioCorRx Begins Recruitment for Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
April 27, 2022 08:30 ET
|
BioCorRx Inc
ANAHEIM, CA, April 27, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and...
BioCorRx Announces Additional Award of Nearly $100,000 from NIDA for BICX104, its Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
April 11, 2022 08:30 ET
|
BioCorRx Inc
ANAHEIM, CA, April 11, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and...